Reactive Robotics is a Munich-based company that specializes in AI- and robot-assisted mobilization in hospitals, geriatrics, and nursing care. Its flagship robotic assistance system, VEMOTION, is designed for patients, caregivers, therapists, and medical professionals and mobilizes critically ill and intensive care patients. VEMOTION physically relieves caregivers and therapists and can work with patients weighing up to 180 kg. The company reports that critically ill and intensive care patients have already received more than 5,000 mobilizations with the system. Reactive Robotics plans to use the new funds to develop its globally AI-supported robotic assistance system and to advance national and international market launch. The recent financing of €5M expands its resources to scale VEMOTION and commercialize the technology. Reactive Robotics builds intelligent, assistive robotics (the VEMO® system) to enable early mobilization therapy for critically ill ICU patients and relieve nursing and therapy staff of physically difficult work. The VEMO® system delivers therapy in the intensive care bed using sensors and robot intelligence to support therapists and avoid dangerous patient transfers. The company received CE approval for VEMO® in 2019 and was one of the first medtech firms certified under the European Medical Device Regulation in August 2020. Reactive Robotics’ robots have been providing therapy in hospitals since 2020, and studies at Charité in Berlin and the Schön Klinik Bad Aibling support the technology’s effectiveness. The team is led by founder Dr. Alexander König and the company was founded in April 2015 in Munich. The new financing is intended to further develop the market potential of their assistive-robotics therapy nationally and internationally. Reactive Robotics develops an intelligent therapy device that replaces manual Very Early Mobilization (VEM) therapy with a robotic solution for intensive-care patients, deployable as early as 24 hours after hospital admission and usable directly in the patient’s bed. The company was founded in 2015 by CEO Dr. Alexander Koenig and is based in Munich, Germany. Since incorporation it has completed prototype development, established a quality management system, and formed cooperation with business partners and suppliers. Financially, the company has just received a second seven-digit funding round. The firm intends to use the proceeds to accelerate its international market entry. The article does not disclose exact round size, valuation, or instrument details. ReActive Robotics develops adaptive and intelligent therapy robotics to automate early neurological and orthopedic mobilization in the intensive care unit. Its system uses robotic modules that can be attached to and detached from the patient bed, allowing patients to be mobilized directly in their hospital bed. The company planned to use Series A funds for the development and clinical validation of several prototypes through 2017. ReActive Robotics scheduled its device to become available in Europe beginning of 2018. The company is led by founder and CEO Dr. Alexander Koenig and is based in Munich, Germany. The firm completed a seven-digit Series A financing to support prototype development and clinical validation.

Total raised

$6M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2024